Last reviewed · How we verify
Group R Rasagiline
At a glance
| Generic name | Group R Rasagiline |
|---|---|
| Also known as | Azilect |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease (PHASE4)
- Azilect + Antidepressant Chart Review
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group R Rasagiline CI brief — competitive landscape report
- Group R Rasagiline updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI